Labiotech iconLabiotechSep 14, 2026

Beyond Ozempic: the GLP-1 landscape in 2026

There is a lot going on in the GLP-1 space, a market that landed $79 billion last year, and could shift significantly in the coming years. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Share this story

Send the public story page.

Useful takeaways from this story.

There is a lot going on in the GLP-1 space, a market that landed $79 billion last year, and could shift significantly in the coming years.

Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Building the complete brief

The page is ready to read now. The fuller skim-friendly version will appear here automatically.

The useful part

There is a lot going on in the GLP-1 space, a market that landed $79 billion last year, and could shift significantly in the coming years. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app